Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting. A randomized, double-blind, placebo-controlled trial.

Waters D, Danska J, Hardy K, Koster F, Qualls C, Nickell D, Nightingale S, Gesundheit N, Watson D, Schade D

Annals of internal medicine1 Dec 1996Cited by 83 (Europe PMC)

PMID8967666DOI10.7326/0003-4819-125-11-199612010-00001PepBankPUB-08967666

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study22

14 results from studies that gave the peptide. 14 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with AIDS wasting, rhIGF-1 alone increased lean body mass at 6 weeks.
In plain wordsIn patients with AIDS wasting, rhIGF-1 alone increased lean body mass at 6 weeks.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseLean body mass at 6 weeks
Study
n = 15
Outcome group
Body composition · Metabolic and weight
Studied dose
5 mg twice dailyAs given in this study (human).
Source sentences
Summary
At 6 weeks, lean body mass had increased and total fat mass had decreased in the groups receiving rhGH, rhIGF-1, or both.
2 context sentences(design, population, supporting numbers)
Summary · context
60 patients with AIDS and wasting as defined by the Centers for Disease Control and Prevention.
Summary · context
Patients were divided into four groups of 15 patients each.
Report a problemFND-0896766601
02HumanRandomized controlled trialEfficacy outcome
In patients with AIDS wasting, rhIGF-1 alone decreased total fat mass at 6 weeks.
In plain wordsIn patients with AIDS wasting, rhIGF-1 alone decreased total fat mass at 6 weeks.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseFat mass at 6 weeks
Study
n = 15
Outcome group
Body composition · Metabolic and weight
Studied dose
5 mg twice dailyAs given in this study (human).
Source sentences
Summary
At 6 weeks, lean body mass had increased and total fat mass had decreased in the groups receiving rhGH, rhIGF-1, or both.
2 context sentences(design, population, supporting numbers)
Summary · context
60 patients with AIDS and wasting as defined by the Centers for Disease Control and Prevention.
Summary · context
Patients were divided into four groups of 15 patients each.
Report a problemFND-0896766602
03HumanRandomized controlled trialEfficacy outcome
In patients with AIDS wasting, rhIGF-1 alone did not maintain body mass changes at 12 weeks.
In plain wordsIn patients with AIDS wasting, rhIGF-1 alone did not maintain body mass changes at 12 weeks.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeBody mass persistence at 12 weeks
Study
n = 15
Outcome group
Body composition · Metabolic and weight
Studied dose
5 mg twice dailyAs given in this study (human).
Source sentences
Summary
Group 3 had the greatest changes in lean body mass (mean +/- SE, 3.2 +/- 0.59 kg; P < 0.001); only in this group were changes in body mass maintained at 12 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
60 patients with AIDS and wasting as defined by the Centers for Disease Control and Prevention.
Summary · context
Patients were divided into four groups of 15 patients each.
Report a problemFND-0896766607
04HumanRandomized controlled trialEfficacy outcome
In patients with AIDS wasting, rhIGF-1 alone did not improve knee muscular strength.
In plain wordsIn patients with AIDS wasting, rhIGF-1 alone did not improve knee muscular strength.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeKnee muscular strength
Study
n = 15
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
5 mg twice dailyAs given in this study (human).
Source sentences
Summary
Only patients in group 1 had improvement in muscular strength of the knees and upper body (P = 0.04) and quality of life (P = 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
Group 1 received 1.4 mg of rhGH once daily plus placebo twice daily; group 2 received 5 mg of rhIGF-1 twice daily plus placebo once daily; group 3 received 5 mg of rhIGF-1 twice daily plus 1.4 mg of rhGH once daily; and group 4 received placebo three times daily.
Summary · context
60 patients with AIDS and wasting as defined by the Centers for Disease Control and Prevention.
Summary · context
Patients were divided into four groups of 15 patients each.
Report a problemFND-0896766608
05HumanRandomized controlled trialEfficacy outcome
In patients with AIDS wasting, rhIGF-1 alone did not improve upper-body muscular strength.
In plain wordsIn patients with AIDS wasting, rhIGF-1 alone did not improve upper-body muscular strength.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeUpper-body muscular strength
Study
n = 15
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
5 mg twice dailyAs given in this study (human).
Source sentences
Summary
Only patients in group 1 had improvement in muscular strength of the knees and upper body (P = 0.04) and quality of life (P = 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
Group 1 received 1.4 mg of rhGH once daily plus placebo twice daily; group 2 received 5 mg of rhIGF-1 twice daily plus placebo once daily; group 3 received 5 mg of rhIGF-1 twice daily plus 1.4 mg of rhGH once daily; and group 4 received placebo three times daily.
Summary · context
60 patients with AIDS and wasting as defined by the Centers for Disease Control and Prevention.
Summary · context
Patients were divided into four groups of 15 patients each.
Report a problemFND-0896766609
06HumanRandomized controlled trialEfficacy outcome
In patients with AIDS wasting, rhIGF-1 alone did not improve quality of life.
In plain wordsIn patients with AIDS wasting, rhIGF-1 alone did not improve quality of life.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeQuality of life
Study
n = 15
Outcome group
Quality of life · Whole body
Studied dose
5 mg twice dailyAs given in this study (human).
Source sentences
Summary
Only patients in group 1 had improvement in muscular strength of the knees and upper body (P = 0.04) and quality of life (P = 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
Group 1 received 1.4 mg of rhGH once daily plus placebo twice daily; group 2 received 5 mg of rhIGF-1 twice daily plus placebo once daily; group 3 received 5 mg of rhIGF-1 twice daily plus 1.4 mg of rhGH once daily; and group 4 received placebo three times daily.
Summary · context
60 patients with AIDS and wasting as defined by the Centers for Disease Control and Prevention.
Summary · context
Patients were divided into four groups of 15 patients each.
Report a problemFND-0896766610
07HumanRandomized controlled trialEfficacy outcome
In patients with AIDS wasting, immunologic function did not improve in any group, including rhIGF-1 alone.
In plain wordsIn patients with AIDS wasting, immune function did not improve in any group, including rhIGF-1 alone.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeImmunologic function
Study
n = 15
Outcome group
Immune response · Immune and inflammation
Studied dose
5 mg twice dailyAs given in this study (human).
Source sentences
Summary
Immunologic function did not improve in any group.
2 context sentences(design, population, supporting numbers)
Summary · context
60 patients with AIDS and wasting as defined by the Centers for Disease Control and Prevention.
Summary · context
Patients were divided into four groups of 15 patients each.
Report a problemFND-0896766614
08HumanNon-randomized trialEfficacy outcome
In patients with AIDS-associated wasting, rhGH alone increased lean body mass at 6 weeks versus baseline.
In plain wordsIn patients with AIDS-associated wasting, rhGH alone increased lean body mass at 6 weeks versus baseline.
Peptide
HGH (somatotropin)
Outcome
IncreaseLean body mass at 6 weeks
Study
n = 15
Comparator
Baseline
Outcome group
Body composition · Musculoskeletal
Studied dose
1.4 mg once dailyAs given in this study (human).
Source sentences
Summary
At 6 weeks, lean body mass had increased and total fat mass had decreased in the groups receiving rhGH, rhIGF-1, or both.
4 context sentences(design, population, supporting numbers)
Summary · context
Randomized, double-blind, placebo-controlled clinical trial.
Summary · context
60 patients with AIDS and wasting as defined by the Centers for Disease Control and Prevention.
Summary · context
Patients were divided into four groups of 15 patients each.
Summary · context
Group 1 received 1.4 mg of rhGH once daily plus placebo twice daily;
Report a problemFND-0896766616
09HumanNon-randomized trialEfficacy outcome
In patients with AIDS-associated wasting, rhGH alone decreased total fat mass at 6 weeks versus baseline.
In plain wordsIn patients with AIDS-associated wasting, rhGH alone decreased total fat mass at 6 weeks versus baseline.
Peptide
HGH (somatotropin)
Outcome
DecreaseTotal fat mass at 6 weeks
Study
n = 15
Comparator
Baseline
Outcome group
Body composition · Metabolic and weight
Studied dose
1.4 mg once dailyAs given in this study (human).
Source sentences
Summary
At 6 weeks, lean body mass had increased and total fat mass had decreased in the groups receiving rhGH, rhIGF-1, or both.
4 context sentences(design, population, supporting numbers)
Summary · context
Randomized, double-blind, placebo-controlled clinical trial.
Summary · context
60 patients with AIDS and wasting as defined by the Centers for Disease Control and Prevention.
Summary · context
Patients were divided into four groups of 15 patients each.
Summary · context
Group 1 received 1.4 mg of rhGH once daily plus placebo twice daily;
Report a problemFND-0896766617
10HumanNon-randomized trialEfficacy outcome
In patients with AIDS-associated wasting, rhGH alone did not maintain body mass changes at 12 weeks.
In plain wordsIn patients with AIDS-associated wasting, rhGH alone did not maintain body mass changes at 12 weeks.
Peptide
HGH (somatotropin)
Outcome
Direction not reportedMaintenance of body mass changes at 12 weeks
Study
n = 15
Outcome group
Body composition · Metabolic and weight
Studied dose
1.4 mg once dailyAs given in this study (human).
Source sentences
Summary
Group 3 had the greatest changes in lean body mass (mean +/- SE, 3.2 +/- 0.59 kg; P < 0.001); only in this group were changes in body mass maintained at 12 weeks.
5 context sentences(design, population, supporting numbers)
Summary · context
Group 1 received 1.4 mg of rhGH once daily plus placebo twice daily; group 2 received 5 mg of rhIGF-1 twice daily plus placebo once daily; group 3 received 5 mg of rhIGF-1 twice daily plus 1.4 mg of rhGH once daily; and group 4 received placebo three times daily.
Summary · context
Randomized, double-blind, placebo-controlled clinical trial.
Summary · context
60 patients with AIDS and wasting as defined by the Centers for Disease Control and Prevention.
Summary · context
Patients were divided into four groups of 15 patients each.
Summary · context
Group 1 received 1.4 mg of rhGH once daily plus placebo twice daily;
Report a problemFND-0896766618
11HumanNon-randomized trialEfficacy outcome
In patients with AIDS-associated wasting, only rhGH alone improved knee muscular strength, with P = 0.04 for the reported strength result.
In plain wordsIn patients with AIDS-associated wasting, only rhGH alone improved knee muscular strength versus baseline.
Peptide
HGH (somatotropin)
Outcome
IncreaseKnee muscular strength
Study
n = 15
Comparator
Baseline
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
1.4 mg once dailyAs given in this study (human).
Measurements
P value
0.04
muscular strength
Source sentences
Summary
Only patients in group 1 had improvement in muscular strength of the knees and upper body (P = 0.04) and quality of life (P = 0.01).
4 context sentences(design, population, supporting numbers)
Summary · context
Randomized, double-blind, placebo-controlled clinical trial.
Summary · context
60 patients with AIDS and wasting as defined by the Centers for Disease Control and Prevention.
Summary · context
Patients were divided into four groups of 15 patients each.
Summary · context
Group 1 received 1.4 mg of rhGH once daily plus placebo twice daily;
Report a problemFND-0896766619
12HumanNon-randomized trialEfficacy outcome
In patients with AIDS-associated wasting, only rhGH alone improved upper body muscular strength, with P = 0.04 for the reported strength result.
In plain wordsIn patients with AIDS-associated wasting, only rhGH alone improved upper body muscular strength versus baseline.
Peptide
HGH (somatotropin)
Outcome
IncreaseUpper body muscular strength
Study
n = 15
Comparator
Baseline
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
1.4 mg once dailyAs given in this study (human).
Measurements
P value
0.04
muscular strength
Source sentences
Summary
Only patients in group 1 had improvement in muscular strength of the knees and upper body (P = 0.04) and quality of life (P = 0.01).
4 context sentences(design, population, supporting numbers)
Summary · context
Randomized, double-blind, placebo-controlled clinical trial.
Summary · context
60 patients with AIDS and wasting as defined by the Centers for Disease Control and Prevention.
Summary · context
Patients were divided into four groups of 15 patients each.
Summary · context
Group 1 received 1.4 mg of rhGH once daily plus placebo twice daily;
Report a problemFND-0896766620
13HumanNon-randomized trialEfficacy outcome
In patients with AIDS-associated wasting, only rhGH alone improved quality of life versus baseline (P = 0.01).
In plain wordsIn patients with AIDS-associated wasting, only rhGH alone improved quality of life versus baseline.
Peptide
HGH (somatotropin)
Outcome
Direction not reportedQuality of life
Study
n = 15
Comparator
Baseline
Outcome group
Quality of life · Whole body
Studied dose
1.4 mg once dailyAs given in this study (human).
Measurements
P value
0.01
quality of life
Source sentences
Summary
Only patients in group 1 had improvement in muscular strength of the knees and upper body (P = 0.04) and quality of life (P = 0.01).
4 context sentences(design, population, supporting numbers)
Summary · context
Randomized, double-blind, placebo-controlled clinical trial.
Summary · context
60 patients with AIDS and wasting as defined by the Centers for Disease Control and Prevention.
Summary · context
Patients were divided into four groups of 15 patients each.
Summary · context
Group 1 received 1.4 mg of rhGH once daily plus placebo twice daily;
Report a problemFND-0896766621
14HumanNon-randomized trialEfficacy outcome
In patients with AIDS-associated wasting, rhGH alone did not improve immunologic function, as in every group.
In plain wordsIn patients with AIDS-associated wasting, rhGH alone did not improve immune function, as in every group.
Peptide
HGH (somatotropin)
Outcome
Direction not reportedImmunologic function
Study
n = 15
Comparator
Baseline
Outcome group
Immune response · Immune and inflammation
Studied dose
1.4 mg once dailyAs given in this study (human).
Source sentences
Summary
Immunologic function did not improve in any group.
4 context sentences(design, population, supporting numbers)
Summary · context
Randomized, double-blind, placebo-controlled clinical trial.
Summary · context
60 patients with AIDS and wasting as defined by the Centers for Disease Control and Prevention.
Summary · context
Patients were divided into four groups of 15 patients each.
Summary · context
Group 1 received 1.4 mg of rhGH once daily plus placebo twice daily;
Report a problemFND-0896766622

Studies that did not test the peptide alone8

In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 (mecasermin).

15HumanNot a test of IGF-1 (mecasermin) aloneRandomized controlled trialEfficacy outcome
In patients with AIDS wasting, combined rhIGF-1 and rhGH increased lean body mass at 6 weeks.
In plain wordsIn patients with AIDS wasting, combined rhIGF-1 and rhGH increased lean body mass at 6 weeks.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseLean body mass at 6 weeks
Study
n = 15
Outcome group
Body composition · Metabolic and weight
Measurements
Mean lean body mass change
3.2 kg
Group 3 (rhIGF-1 plus rhGH), 6 weeks, mean +/- SE 3.2 +/- 0.59 kg
p value for lean body mass change in group 3
< 0.001 p value
Group 3 (rhIGF-1 plus rhGH), lean body mass change at 6 weeks, reference comparison not specified
Source sentences
Summary
At 6 weeks, lean body mass had increased and total fat mass had decreased in the groups receiving rhGH, rhIGF-1, or both.
Summary
Group 3 had the greatest changes in lean body mass (mean +/- SE, 3.2 +/- 0.59 kg; P < 0.001); only in this group were changes in body mass maintained at 12 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
60 patients with AIDS and wasting as defined by the Centers for Disease Control and Prevention.
Summary · context
Patients were divided into four groups of 15 patients each.
In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).
Report a problemFND-0896766603
16HumanNot a test of IGF-1 (mecasermin) aloneRandomized controlled trialEfficacy outcome
In patients with AIDS wasting, combined rhIGF-1 and rhGH decreased total fat mass at 6 weeks.
In plain wordsIn patients with AIDS wasting, combined rhIGF-1 and rhGH decreased total fat mass at 6 weeks.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseFat mass at 6 weeks
Study
n = 15
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
At 6 weeks, lean body mass had increased and total fat mass had decreased in the groups receiving rhGH, rhIGF-1, or both.
2 context sentences(design, population, supporting numbers)
Summary · context
60 patients with AIDS and wasting as defined by the Centers for Disease Control and Prevention.
Summary · context
Patients were divided into four groups of 15 patients each.
In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).
Report a problemFND-0896766604
17HumanNot a test of IGF-1 (mecasermin) aloneRandomized controlled trialEfficacy outcome
In patients with AIDS wasting, combined rhIGF-1 and rhGH produced the greatest lean body mass change, 3.2 kg.
In plain wordsIn patients with AIDS wasting, combined rhIGF-1 and rhGH produced the greatest lean body mass change, 3.2 kg.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseLean body mass change
Study
n = 15
Outcome group
Body composition · Metabolic and weight
Measurements
Lean body mass change
3.2 kg
Group 3 (rhIGF-1 plus rhGH), mean +/- SE 3.2 +/- 0.59
p value for lean body mass change in group 3
< 0.001 p value
Group 3 (rhIGF-1 plus rhGH), lean body mass change at 6 weeks, reference comparison not specified
Source sentences
Summary
Group 3 had the greatest changes in lean body mass (mean +/- SE, 3.2 +/- 0.59 kg; P < 0.001); only in this group were changes in body mass maintained at 12 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
60 patients with AIDS and wasting as defined by the Centers for Disease Control and Prevention.
Summary · context
Patients were divided into four groups of 15 patients each.
In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).
Report a problemFND-0896766605
18HumanNot a test of IGF-1 (mecasermin) aloneRandomized controlled trialEfficacy outcome
In patients with AIDS wasting, only combined rhIGF-1 and rhGH maintained body mass changes at 12 weeks.
In plain wordsIn patients with AIDS wasting, only combined rhIGF-1 and rhGH maintained body mass changes at 12 weeks.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseBody mass persistence at 12 weeks
Study
n = 15
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
Group 3 had the greatest changes in lean body mass (mean +/- SE, 3.2 +/- 0.59 kg; P < 0.001); only in this group were changes in body mass maintained at 12 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
60 patients with AIDS and wasting as defined by the Centers for Disease Control and Prevention.
Summary · context
Patients were divided into four groups of 15 patients each.
In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).
Report a problemFND-0896766606
19HumanNot a test of IGF-1 (mecasermin) aloneRandomized controlled trialEfficacy outcome
In patients with AIDS wasting, combined rhIGF-1 and rhGH did not improve knee muscular strength.
In plain wordsIn patients with AIDS wasting, combined rhIGF-1 and rhGH did not improve knee muscular strength.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeKnee muscular strength
Study
n = 15
Outcome group
Exercise and physical function · Musculoskeletal
Source sentences
Summary
Only patients in group 1 had improvement in muscular strength of the knees and upper body (P = 0.04) and quality of life (P = 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
Group 1 received 1.4 mg of rhGH once daily plus placebo twice daily; group 2 received 5 mg of rhIGF-1 twice daily plus placebo once daily; group 3 received 5 mg of rhIGF-1 twice daily plus 1.4 mg of rhGH once daily; and group 4 received placebo three times daily.
Summary · context
60 patients with AIDS and wasting as defined by the Centers for Disease Control and Prevention.
Summary · context
Patients were divided into four groups of 15 patients each.
In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).
Report a problemFND-0896766611
20HumanNot a test of IGF-1 (mecasermin) aloneRandomized controlled trialEfficacy outcome
In patients with AIDS wasting, combined rhIGF-1 and rhGH did not improve upper-body muscular strength.
In plain wordsIn patients with AIDS wasting, combined rhIGF-1 and rhGH did not improve upper-body muscular strength.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeUpper-body muscular strength
Study
n = 15
Outcome group
Exercise and physical function · Musculoskeletal
Source sentences
Summary
Only patients in group 1 had improvement in muscular strength of the knees and upper body (P = 0.04) and quality of life (P = 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
Group 1 received 1.4 mg of rhGH once daily plus placebo twice daily; group 2 received 5 mg of rhIGF-1 twice daily plus placebo once daily; group 3 received 5 mg of rhIGF-1 twice daily plus 1.4 mg of rhGH once daily; and group 4 received placebo three times daily.
Summary · context
60 patients with AIDS and wasting as defined by the Centers for Disease Control and Prevention.
Summary · context
Patients were divided into four groups of 15 patients each.
In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).
Report a problemFND-0896766612
21HumanNot a test of IGF-1 (mecasermin) aloneRandomized controlled trialEfficacy outcome
In patients with AIDS wasting, combined rhIGF-1 and rhGH did not improve quality of life.
In plain wordsIn patients with AIDS wasting, combined rhIGF-1 and rhGH did not improve quality of life.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeQuality of life
Study
n = 15
Outcome group
Quality of life · Whole body
Source sentences
Summary
Only patients in group 1 had improvement in muscular strength of the knees and upper body (P = 0.04) and quality of life (P = 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
Group 1 received 1.4 mg of rhGH once daily plus placebo twice daily; group 2 received 5 mg of rhIGF-1 twice daily plus placebo once daily; group 3 received 5 mg of rhIGF-1 twice daily plus 1.4 mg of rhGH once daily; and group 4 received placebo three times daily.
Summary · context
60 patients with AIDS and wasting as defined by the Centers for Disease Control and Prevention.
Summary · context
Patients were divided into four groups of 15 patients each.
In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).
Report a problemFND-0896766613
22HumanNot a test of IGF-1 (mecasermin) aloneRandomized controlled trialEfficacy outcome
In patients with AIDS wasting, immune function did not improve in any group, including combined rhIGF-1 and rhGH.
In plain wordsIn patients with AIDS wasting, immune function did not improve in any group, including combined rhIGF-1 and rhGH.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeImmunologic function
Study
n = 15
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
Immunologic function did not improve in any group.
2 context sentences(design, population, supporting numbers)
Summary · context
60 patients with AIDS and wasting as defined by the Centers for Disease Control and Prevention.
Summary · context
Patients were divided into four groups of 15 patients each.
In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).
Report a problemFND-0896766615

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
27 Oct 2026, 16:37 UTC
Study data updated · source update from Europe PMC
Version 2
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting. A randomized, double-blind, placebo-controlled trial.

Summary

Results from this study22

Studies that did not test the peptide alone8

Version history

Subjects

Publication types

MeSH terms